US Drug Recall Register
Class III · Low risk Terminated Initiated Nov 15, 2019 (7 years ago)

Clobetasol Propionate Foam

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Defective delivery system; product is not foaming or is coming out as liquid.

What was recalled

Clobetasol Propionate Foam (Emulsion Formulation), 0.05% a) 50 g pack (NDC 68462-625-27) and b) 100 g pack (NDC 68462-625-94), Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited Plot No. B-25, MIDC, Shendra Aurangabad, Maharashtra -431210, India Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430

Recalling firm
Glenmark Pharmaceuticals Inc., USA
NDC code
68462-625-27
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0619-2020

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Clobetasol recalls

See all
Class II · Moderate risk Ongoing

Clobetasol Propionate Shampoo

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0796-2023
Class II · Moderate risk Ongoing

Clobetasol Propionate Ointment

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0795-2023
Class II · Moderate risk Ongoing

Clobetasol Propionate Cream

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0794-2023
Class III · Low risk Terminated

Clobetasol propionate Cream USP

Reason Subpotent Drug: Low assay result observed during long-term stability testing.

Lupin Pharmaceuticals Inc. NDC 68180-956-03 D-0174-2023
Class II · Moderate risk Terminated

Clobetasol Propionate Lotion 0.05%

Reason CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc. is discontinuing its stability study program.

Preferred Pharmaceuticals, Inc. NDC 68788-7768-01 D-0768-2022